直接转运至可取栓中心与转运至当地卒中中心对疑似大血管闭塞卒中患者神经功能结局的影响:RACECAT随机临床试验
RACECAT为多中心、基于人群的整群随机试验,纳入2017年3月至2020年6月西班牙加泰罗尼亚非城市地区急救系统接诊的1401例疑似急性大血管闭塞卒中患者,比较直接转运至可取栓中心(n=688)与转运至最近当地卒中中心(n=713)。主要终点为目标缺血性卒中人群(n=949)90天改良Rankin量表(mRS)评分,两组中位mRS均为3分(IQR 2-5),校正共同OR 1.03(95%CI 0.82-1.29)。直接转运组静脉tPA使用率更低(47.5% vs 60.4%;OR 0.59;95%CI 0.45-0.76),取栓率更高(48.8% vs 39.4%;OR 1.46;95%CI 1.13-1.89);90天死亡率无显著差异(27.3% vs 27.2%;校正HR 0.97;95%CI 0.79-1.18)。作者结论认为需在其他场景重复验证。
要点
- 目标缺血性卒中人群90天中位mRS评分直接转运组3分(IQR 2-5) vs 当地卒中中心组3分(IQR 2-5),校正共同OR 1.03(95%CI 0.82-1.29),无显著差异。
- 目标人群静脉tPA使用率直接转运组47.5%(229/482) vs 当地卒中中心组60.4%(282/467),OR 0.59(95%CI 0.45-0.76),直接转运组显著更低。
- 目标人群取栓率直接转运组48.8%(235/482) vs 当地卒中中心组39.4%(184/467),OR 1.46(95%CI 1.13-1.89),直接转运组显著更高。
- 安全人群90天死亡率直接转运组27.3%(188/688) vs 当地卒中中心组27.2%(194/713),校正HR 0.97(95%CI 0.79-1.18),无显著差异。
- 11项次要结局中8项无显著差异;试验在第二次期中分析后因无效而停止入组。
适用人群与场景
- 西班牙加泰罗尼亚非城市地区,急救系统接诊的疑似急性大血管闭塞卒中患者,且最近当地卒中中心不能实施取栓。
- 纳入1401例随机患者(直接转运组688例,当地卒中中心组713例);1369例(98%)同意参与并纳入按随机分析(男性56%;中位年龄75岁,IQR 65-83;中位NIHSS评分17,IQR 11-21);949例(69%)构成目标缺血性卒中人群纳入主要分析。
诊断标准与关键阈值
- 疑似急性大血管闭塞卒中由急救系统现场判断。
- 主要结局采用改良Rankin量表(mRS)评估90天残疾,评分范围0分(无症状)至6分(死亡)。
处置流程与药物剂量
- 干预为直接转运至可取栓中心(n=688)或转运至最近当地卒中中心(n=713)。
- 目标人群静脉tPA使用率直接转运组47.5%(229/482) vs 当地卒中中心组60.4%(282/467);取栓率直接转运组48.8%(235/482) vs 当地卒中中心组39.4%(184/467)。
研究设计与关键结果
- 研究类型:多中心、基于人群的整群随机试验;纳入1401例疑似急性大血管闭塞卒中患者;干预为直接转运至可取栓中心(n=688) vs 最近当地卒中中心(n=713)。
- 主要终点:目标缺血性卒中人群(n=949)90天mRS评分中位数直接转运组3分(IQR 2-5) vs 当地卒中中心组3分(IQR 2-5),校正共同OR 1.03(95%CI 0.82-1.29)。
- 次要终点:目标人群静脉tPA使用率直接转运组47.5%(229/482) vs 当地卒中中心组60.4%(282/467),OR 0.59(95%CI 0.45-0.76);取栓率直接转运组48.8%(235/482) vs 当地卒中中心组39.4%(184/467),OR 1.46(95%CI 1.13-1.89)。
- 11项次要结局中8项无显著差异。
- 安全性:安全人群90天死亡率直接转运组27.3%(188/688) vs 当地卒中中心组27.2%(194/713),校正HR 0.97(95%CI 0.79-1.18)。
- 试验在第二次期中分析后因无效停止入组;最终随访日期为2020年9月。
证据类型、等级与局限
- 证据类型:多中心、基于人群的整群随机试验(RACECAT)。
- 局限:作者结论指出这些发现需在其他场景重复验证。
对床旁实践的改变
- 在西班牙加泰罗尼亚非城市地区,对疑似大血管闭塞卒中患者,直接转运至可取栓中心与转运至最近当地卒中中心相比,90天神经功能结局无显著差异;作者结论认为需在其他场景重复验证。
- 直接转运至可取栓中心与静脉tPA使用率更低相关(47.5% vs 60.4%;OR 0.59;95%CI 0.45-0.76),与取栓率更高相关(48.8% vs 39.4%;OR 1.46;95%CI 1.13-1.89)。
指南或共识出处
- RACECAT随机临床试验(ClinicalTrials.gov注册号NCT02795962),发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In nonurban areas with limited access to thrombectomy-capable centers, optimal prehospital transport strategies in patients with suspected large-vessel occlusion stroke are unknown.
OBJECTIVE: To determine whether, in nonurban areas, direct transport to a thrombectomy-capable center is beneficial compared with transport to the closest local stroke center.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, population-based, cluster-randomized trial including 1401 patients with suspected acute large-vessel occlusion stroke attended by emergency medical services in areas where the closest local stroke center was not capable of performing thrombectomy in Catalonia, Spain, between March 2017 and June 2020. The date of final follow-up was September 2020.
INTERVENTIONS: Transportation to a thrombectomy-capable center (n = 688) or the closest local stroke center (n = 713).
MAIN OUTCOMES AND MEASURES: The primary outcome was disability at 90 days based on the modified Rankin Scale (mRS; scores range from 0 [no symptoms] to 6 [death]) in the target population of patients with ischemic stroke. There were 11 secondary outcomes, including rate of intravenous tissue plasminogen activator administration and thrombectomy in the target population and 90-day mortality in the safety population of all randomized patients.
RESULTS: Enrollment was halted for futility following a second interim analysis. The 1401 enrolled patients were included in the safety analysis, of whom 1369 (98%) consented to participate and were included in the as-randomized analysis (56% men; median age, 75 [IQR, 65-83] years; median National Institutes of Health Stroke Scale score, 17 [IQR, 11-21]); 949 (69%) comprised the target ischemic stroke population included in the primary analysis. For the primary outcome in the target population, median mRS score was 3 (IQR, 2-5) vs 3 (IQR, 2-5) (adjusted common odds ratio [OR], 1.03; 95% CI, 0.82-1.29). Of 11 reported secondary outcomes, 8 showed no significant difference. Compared with patients first transported to local stroke centers, patients directly transported to thrombectomy-capable centers had significantly lower odds of receiving intravenous tissue plasminogen activator (in the target population, 229/482 [47.5%] vs 282/467 [60.4%]; OR, 0.59; 95% CI, 0.45-0.76) and significantly higher odds of receiving thrombectomy (in the target population, 235/482 [48.8%] vs 184/467 [39.4%]; OR, 1.46; 95% CI, 1.13-1.89). Mortality at 90 days in the safety population was not significantly different between groups (188/688 [27.3%] vs 194/713 [27.2%]; adjusted hazard ratio, 0.97; 95% CI, 0.79-1.18).
CONCLUSIONS AND RELEVANCE: In nonurban areas in Catalonia, Spain, there was no significant difference in 90-day neurological outcomes between transportation to a local stroke center vs a thrombectomy-capable referral center in patients with suspected large-vessel occlusion stroke. These findings require replication in other settings.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02795962.
参考来源
- Pérez de la Ossa N, Abilleira S, Jovin TG, et al. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA. 2022. PMID: 35510397. doi:10.1001/jama.2022.4404
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。